SOURCE: Graybug Vision, Inc.

Graybug Vision, Inc.

May 08, 2017 08:00 ET

Graybug Vision's Potential Once-Per-Year AMD Treatment Data Presented at ARVO 2017

Company Developing Injectable Products for Treating Glaucoma and AMD

REDWOOD CITY, CA--(Marketwired - May 8, 2017) - Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that data from its preclinical research will be highlighted in presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting, taking place May 7 to 11 in Baltimore, MD.

Graybug Vision has two products in preclinical development for the treatment of ocular diseases. Its lead product, GB-102, is a novel injectable depot formulation containing a compound blocking angiogenesis pathways through multiple receptors (e.g., VEGFR) for the potentially twice per year treatment of wet AMD. A Phase 1/2 study of GB-102 in wet AMD patients will be initiated in Q3 2017. The ARVO presentation will highlight the second-generation GB-102 product for potential once per year treatment of wet AMD. A second novel compound for the twice per year treatment of glaucoma is moving through preclinical studies.

On May 8th, Graybug Vision Senior Vice President of Preclinical Development Ward M. Peterson, PhD, will present data from a preclinical study of sunitinib in a poster entitled: "Ocular metabolism and melanin binding properties of sunitinib, a dual VEGFR/PDGFR inhibitor, that can safely prolong its efficacy for the treatment of wet AMD."

On May 10th, Graybug Vision Director of Research Ming Yang, PhD, will present data two preclinical studies of GB-102 in the morning poster session. The two posters are entitled: "Modifications of Sunitinib-Loaded GB-102 Microparticles that Lengthen Drug Release: 9-Months Ocular Tolerability and PK in Rabbit Following IVT Dosing" and "Prodrugs of carbonic anhydrase inhibitors to enable continuous delivery from a depot for up to 6 months after subconjunctival delivery."

Also on May 10th, Graybug Vision Chief Medical Officer Charles Semba, MD, will participate in a Special Interest Group presentation entitled: "Highlighting Successful Technologies in Sustained Drug Delivery in Ophthalmology: New Polymer Science and Particle Engineering Platforms that Drive Future Promising Extended Release Therapies."

Details of the presentations are as follows:

Title: Ocular metabolism and melanin binding properties of sunitinib, a dual VEGFR/PDGFR inhibitor, that can safely prolong its efficacy for the treatment of wet AMD
Poster Number: 1974-B0478
Session Number: 249
Session Title: AMD: New Drugs, delivery systems
Date: Monday, May 8, 2017
Time: 11:00 AM to 12:45 PM

Title: Modifications of Sunitinib-Loaded GB-102 Microparticles that Lengthen Drug Release: 9-Months Ocular Tolerability and PK in Rabbit Following IVT Dosing
Poster Number: 4115 - B0115
Session Number: 424
Session Title: Drug and gene therapy and delivery
Date: Wednesday, May 10, 2017
Time: 8:30 AM to 10:15 AM

Title: Prodrugs of carbonic anhydrase inhibitors to enable continuous delivery from a depot for up to 6 months after subconjunctival delivery
Poster Number: 4118- B0118
Session Number: 424
Session Title: Drug and gene therapy and delivery
Date: Wednesday, May 10, 2017
Time: 8:30 AM to 10:15 AM

Title: Highlighting Successful Technologies in Sustained Drug Delivery in Ophthalmology: New Polymer Science and Particle Engineering Platforms that Drive Future Promising Extended Release Therapies
Session Number: 464
Session Title: Special Interest Group (SIG) presentation
Date: Wednesday, May 10, 2017
Time: 1:00 PM to 2:30 PM
Room: 321

About Graybug Vision
Graybug Vision is developing novel products for the treatment of people with ocular diseases. The company's proprietary injectable products are designed to enable less frequent administration and to reduce the burden of treatment for patients with ocular diseases. The company's lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD. Graybug Vision has developed a library of compounds to treat glaucoma, a leading cause of progressive, irreversible vision loss worldwide, by lowering intraocular pressure alone or in combination with neuroprotection when injected twice per year into the subconjunctiva. For more information, please visit www.graybug.com.

Contact Information

  • CONTACTS:
    Graybug Vision, Inc. Corporate
    Jeffrey L. Cleland, PhD
    650-487-2808
    Email Contact
    or
    Graybug Vision, Inc. Media
    Debra Bannister
    530-676-7373
    Email Contact